Biomind Labs Inc. (BMNDF)
USD 0.31
(0.0%)
USD 0.31
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.03 Million USD | 65.61% |
| 2022 | -2.89 Million USD | 14.97% |
| 2021 | -3.39 Million USD | -1688.76% |
| 2020 | 36.49 Million USD | 32.04% |
| 2019 | -363.59 Thousand USD | 82.24% |
| 2018 | -1.11 Million USD | -1.36% |
| 2017 | -1.55 Million USD | -87.41% |
| 2016 | -865.68 Thousand USD | 47.15% |
| 2015 | -867.29 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -107.95 Thousand USD | 6.48% |
| 2024 Q2 | -106.28 Thousand USD | -16.28% |
| 2023 Q2 | -351.32 Thousand USD | 13.5% |
| 2023 Q3 | -126.4 Thousand USD | 64.02% |
| 2023 Q4 | -94.9 Thousand USD | 24.92% |
| 2023 Q1 | -406.15 Thousand USD | 21.11% |
| 2023 FY | - USD | 65.61% |
| 2022 Q1 | -712.81 Thousand USD | 39.2% |
| 2022 FY | - USD | 14.97% |
| 2022 Q4 | -514.82 Thousand USD | 42.17% |
| 2022 Q3 | -890.24 Thousand USD | -16.12% |
| 2022 Q2 | -766.63 Thousand USD | -7.55% |
| 2021 Q1 | -295.05 Thousand USD | 0.0% |
| 2021 Q4 | -1.17 Million USD | 29.46% |
| 2021 Q2 | -265.8 Thousand USD | 9.91% |
| 2021 Q3 | -1.66 Million USD | -525.3% |
| 2021 FY | - USD | -1688.76% |
| 2020 Q1 | 14.67 Thousand USD | 0.0% |
| 2020 FY | - USD | 32.04% |
| 2019 FY | - USD | 82.24% |
| 2018 FY | - USD | -1.36% |
| 2017 FY | - USD | -87.41% |
| 2016 FY | - USD | 47.15% |
| 2015 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 98.544% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 82.551% |
| SQZ Biotechnologies Company | -64.14 Million USD | 98.387% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 94.044% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 101.1% |
| Mesoblast Limited | -62.38 Million USD | 98.342% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 32.649% |
| Genus plc | 73.7 Million USD | 101.404% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 84.352% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 70.833% |
| Marizyme, Inc. | -34.28 Million USD | 96.982% |
| ContraFect Corporation | -64.99 Million USD | 98.408% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 88.206% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 77.143% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 26.199% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 60.878% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 55.481% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -99.702% |
| Accustem Sciences Inc. | -3.74 Million USD | 72.386% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 97.855% |
| EV Biologics, Inc. | -1.26 Million USD | 18.355% |
| Q BioMed Inc. | -617.62 Thousand USD | -67.504% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 128.963% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -63.589% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 54.714% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 110.474% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 85.554% |
| Skye Bioscience, Inc. | -13.54 Million USD | 92.364% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 30.446% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -4038.196% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 73.366% |
| IMV Inc. | -35.52 Million USD | 97.088% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 93.481% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 58.65% |
| GB Sciences, Inc. | -1.41 Million USD | 27.139% |
| Alpha Cognition Inc. | -9.7 Million USD | 89.341% |
| HST Global, Inc. | -5303.00 USD | -19408.75% |
| CSL Limited | 4.78 Billion USD | 100.022% |
| Halberd Corporation | -74.27 Thousand USD | -1292.788% |
| Enzolytics Inc. | -2.12 Million USD | 51.247% |
| Resverlogix Corp. | -11.74 Million USD | 91.189% |
| Affymax, Inc. | -14.29 Million USD | 92.763% |
| SYBLEU INC | -141.57 Thousand USD | -630.763% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 66.224% |
| argenx SE | -216.02 Million USD | 99.521% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 98.131% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 185.008% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 30.98% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 373.08% |
| AVAX Technologies, Inc. | -6.11 Million USD | 83.075% |
| Zenith Capital Corp. | -8.6 Million USD | 87.979% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.584% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -5838.517% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 57.712% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -487.731% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 97.39% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 64.231% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 1.124% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 15485.916% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 40.883% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 46.143% |
| BioStem Technologies, Inc. | -7.55 Million USD | 86.304% |
| ONE Bio Corp. | 13.61 Million USD | 107.6% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -471.296% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 49.706% |
| Agentix Corp. | -1.37 Million USD | 24.582% |
| LadRx Corporation | 412.28 Thousand USD | 350.932% |
| Cell Source, Inc. | -4.27 Million USD | 75.786% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -181.724% |
| Regen BioPharma, Inc. | 1.46 Million USD | 170.572% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -10.417% |
| NovAccess Global Inc. | -1.03 Million USD | 0.024% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 111.685% |
| Itoco Inc. | -1.86 Million USD | 44.647% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -172.522% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 7.298% |
| Kadimastem Ltd | -2.62 Million USD | 60.579% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -332.594% |
| CytoDyn Inc. | -18.02 Million USD | 94.262% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -1209.075% |
| Mobile Lads Corp. | -2.24 Million USD | 53.839% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -8359.8% |
| Qrons Inc. | -40.08 Thousand USD | -2481.146% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -113.011% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 296.148% |
| Rebus Holdings, Inc. | -951 Thousand USD | -8.785% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 2.586% |
| International Stem Cell Corporation | 202 Thousand USD | 612.153% |
| Bioxytran, Inc. | -3.82 Million USD | 72.919% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -1865.329% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 57.978% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 97.116% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -2198.998% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 62.215% |
| Neutra Corp. | -181.24 Thousand USD | -470.795% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 94.868% |
| PureTech Health plc | -11.62 Million USD | 91.102% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 94.868% |
| IXICO plc | -707 Thousand USD | -46.329% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 86.538% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 97.86% |
| CSL Limited | 4.73 Billion USD | 100.022% |
| Cellectis S.A. | -92.63 Million USD | 98.883% |